Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell will also end development of ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...